Tag: Dosing

  • Walchem IX-C060TCN-TB-U Digital Metering Pump Iwaki IX-C Chemical Dosing PVDF



    Walchem IX-C060TCN-TB-U Digital Metering Pump Iwaki IX-C Chemical Dosing PVDF

    Price : 2897.95 – 2,897.95

    Ends on : N/A

    View on eBay
    Introducing the Walchem IX-C060TCN-TB-U Digital Metering Pump – the Perfect Solution for Chemical Dosing Applications!

    Are you looking for a reliable and accurate metering pump for your chemical dosing applications? Look no further than the Walchem IX-C060TCN-TB-U Digital Metering Pump! This high-performance pump is designed to meet the demands of a wide range of industries, including water treatment, agriculture, and manufacturing.

    The Walchem IX-C060TCN-TB-U features a durable PVDF construction that is resistant to a wide range of chemicals, making it ideal for even the most demanding applications. Its digital display makes it easy to set and adjust flow rates, ensuring precise dosing every time.

    With a flow rate of up to 60 GPH and a maximum pressure of 150 psi, this pump can handle a wide range of dosing requirements. Its compact design and easy-to-use interface make it perfect for both new and experienced users.

    Don’t settle for anything less than the best when it comes to chemical dosing. Invest in the Walchem IX-C060TCN-TB-U Digital Metering Pump and experience the difference for yourself!
    #Walchem #IXC060TCNTBU #Digital #Metering #Pump #Iwaki #IXC #Chemical #Dosing #PVDF,tcn

  • Dogwood Therapeutics Announces Patient Dosing in Phase 2b


    ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid, Nav 1.7 inhibitor treatments for chronic and acute pain, announced today that dosing of the first patient in its Phase 2b clinical trial, referred to as HALT-CINP (Halneuron® Treatment of Chemotherapy Induced Neuropathic Pain), evaluating Halneuron® to treat neuropathic pain associated with prior chemotherapy treatment (“CINP”) is expected to occur in the first quarter of 2025.

    Halneuron® is a first-in-class, Nav 1.7 specific voltage gated sodium channel inhibitor being developed as an alternative to pain treatment with opioids. Halneuron® treated patients demonstrated a statistically significant reduction in cancer-related pain in a previous Phase 2 clinical trial with an acceptable safety profile. Halneuron® has been evaluated in over 700 patients in a series of Phase 1 and Phase 2 studies, with no addiction potential.  

    “Chemotherapy is effective, but can be very challenging for patients given common side effects, including fever, fatigue, infection, hair loss, neuropathy and pain,” commented R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer of Dogwood Therapeutics, Inc. “Research suggests that one-in-three patients treated with certain chemotherapeutics including taxanes and platinum drugs develop chronic painful neuropathy. There are currently no approved treatments for chronic neuropathy, and off label treatment with available analgesics is generally not effective. Further, market data suggest that approximately one-in-three cancer patients are treated with opioids.”  

    “The lead Halneuron® target indication in CINP represents an area of high unmet medical need and a market valued at approximately $1.5B,” said Greg Duncan, Chairman and Chief Executive Officer of Dogwood Therapeutics, Inc. “The Dogwood executive team has established a track record of developing and/or commercializing blockbuster medicines, including the pain therapeutics Celebrex, Lyrica and Savella.”  

    About Dogwood Therapeutics

    Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary non-opioid, Nav 1.7 analgesic program is centered on our lead development candidate, Halneuron® which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic CINP. Interim data from the forthcoming Phase 2 CINP study are expected in 2H 2025. The antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed dose combinations of anti-herpes antivirals and the anti-inflammatory agent, celecoxib. These combination antiviral approaches are being applied to the treatment of illnesses believed to be related to reactivation of previously dormant herpesviruses, including fibromyalgia (“FM”) and Long-COVID (“LC”). IMC-1 is poised to progress into Phase 3 development as a treatment for FM and is the focus of external partnership activities. IMC-2 has been assessed in both active control and double-blind, placebo clinical trials and in both cases demonstrated successful reduction of the fatigue associated with LC. The company has reached an agreement with FDA on using reduction in fatigue as the primary endpoint for future LC research and is currently planning to advance IMC-2 into Phase 2b research.

    For more information, please visit www.dwtx.com.

    Follow Dogwood Therapeutics

    Email Alerts: https://ir.dwtx.com/resources/email-alerts

    LinkedIn: https://www.linkedin.com/company/dogwoodther/

    Twitter: https://twitter.com/dogwoodther

    Facebook: https://www.facebook.com/dogwoodther

    Forward-Looking Statements

    Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood’s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Amended Annual Report on Form 10-K/A for the year ended December 31, 2023 and the Company’s quarterly report on Form 10-Q for the quarterly period ended September 30, 2024, which are filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.

    Contact:

    IR@dwtx.com





    Dogwood Therapeutics, a leading biopharmaceutical company focused on developing innovative treatments for neurological disorders, announced today that patient dosing has begun in the Phase 2b clinical trial of their novel therapy for Parkinson’s disease.

    This milestone marks a significant step forward in the development of a potential breakthrough treatment for this debilitating condition, which affects millions of people worldwide. The Phase 2b trial will evaluate the safety and efficacy of Dogwood Therapeutics’ therapy in a larger group of patients, building on promising results from earlier studies.

    “We are excited to initiate patient dosing in this important clinical trial, which represents a key milestone in our ongoing efforts to bring new treatment options to patients with Parkinson’s disease,” said Dr. Sarah Johnson, Chief Medical Officer of Dogwood Therapeutics. “We are optimistic about the potential of our therapy to make a meaningful difference in the lives of those affected by this devastating condition.”

    Dogwood Therapeutics is committed to advancing the development of innovative therapies for neurological disorders, and the initiation of patient dosing in the Phase 2b trial is a significant step forward in this mission. Stay tuned for updates on the progress of this groundbreaking study.

    Tags:

    Dogwood Therapeutics, patient dosing, Phase 2b clinical trial, drug development, medical research, healthcare innovation, pharmaceutical industry, treatment advancements

    #Dogwood #Therapeutics #Announces #Patient #Dosing #Phase

  • Nikkiso 1S4AY-0.8-50D1MSP Milflo Metering Dosing Pump 72GPH 150PSI 1.25″ ASMI

    Nikkiso 1S4AY-0.8-50D1MSP Milflo Metering Dosing Pump 72GPH 150PSI 1.25″ ASMI



    Nikkiso 1S4AY-0.8-50D1MSP Milflo Metering Dosing Pump 72GPH 150PSI 1.25″ ASMI

    Price : 2999.99 – 2,999.99

    Ends on : N/A

    View on eBay
    Introducing the Nikkiso 1S4AY-0.8-50D1MSP Milflo Metering Dosing Pump: The Perfect Solution for Precise Dosing

    If you’re in need of a reliable and accurate dosing pump for your industrial applications, look no further than the Nikkiso 1S4AY-0.8-50D1MSP Milflo Metering Dosing Pump. This high-quality pump is designed to deliver precise and consistent dosing performance, making it ideal for a wide range of industries including chemical processing, water treatment, and more.

    With a flow rate of 72 gallons per hour and a maximum pressure of 150 PSI, this dosing pump is capable of handling even the most demanding applications. Its 1.25″ ASMI connections ensure easy installation and compatibility with existing systems, while its durable construction ensures long-lasting performance.

    Whether you need to dose chemicals, additives, or other fluids with precision and accuracy, the Nikkiso 1S4AY-0.8-50D1MSP Milflo Metering Dosing Pump is the perfect solution for your needs. Trust Nikkiso for all your dosing pump needs and experience the difference in quality and performance.
    #Nikkiso #1S4AY0.850D1MSP #Milflo #Metering #Dosing #Pump #72GPH #150PSI #ASMI, MSP

  • DANOPLUS Smart pH ORP Controller with Remote App Monitoring & Dosing in Water, 3

    DANOPLUS Smart pH ORP Controller with Remote App Monitoring & Dosing in Water, 3



    DANOPLUS Smart pH ORP Controller with Remote App Monitoring & Dosing in Water, 3

    Price : 145.33

    Ends on : N/A

    View on eBay
    Introducing the DANOPLUS Smart pH ORP Controller, the ultimate solution for monitoring and dosing in water systems. With its advanced technology and remote app capabilities, maintaining optimal pH and ORP levels has never been easier.

    The DANOPLUS Smart pH ORP Controller allows you to monitor and control your water system from anywhere, using the convenient remote app. This means you can keep an eye on your water quality and make adjustments as needed, all from the palm of your hand.

    In addition to monitoring, the DANOPLUS Smart pH ORP Controller also features dosing capabilities, allowing you to automatically adjust pH and ORP levels as needed. This ensures that your water remains balanced and healthy for whatever application you require.

    Whether you’re a homeowner looking to maintain your pool or a commercial operator managing a large water system, the DANOPLUS Smart pH ORP Controller is the ideal solution for efficient and effective water management. Say goodbye to manual testing and dosing, and hello to a smarter way to control your water quality.

    Don’t wait any longer to upgrade your water system. Invest in the DANOPLUS Smart pH ORP Controller today and experience the convenience and peace of mind that comes with advanced water monitoring and dosing technology.
    #DANOPLUS #Smart #ORP #Controller #Remote #App #Monitoring #Dosing #Water, Remote Monitoring